Gilead Sciences: Clinical Trials

1,211 trials sponsored by Gilead Sciences, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

751 completed, 167 terminated, 83 recruiting, 73 active not recruiting. 406 Phase 2, 275 Phase 3, 226 Phase 1, 148 Phase 4, 95 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2406Completed 236, Terminated 73, Active not recruiting 35, Recruiting 35, Withdrawn 14, Not yet recruiting 6, Unknown 5, Suspended 2
Phase 3275Completed 188, Terminated 42, Active not recruiting 24, Recruiting 10, Not yet recruiting 4, Unknown 4, Withdrawn 3
Phase 1226Completed 136, Terminated 43, Recruiting 19, Withdrawn 10, Active not recruiting 9, Not yet recruiting 4, Unknown 3, Enrolling by invitation 1, Suspended 1
Phase 4148Completed 97, Terminated 18, Unknown 16, Active not recruiting 5, Withdrawn 5, Recruiting 4, Not yet recruiting 3
Not applicable95Completed 58, Recruiting 9, Unknown 8, Withdrawn 8, Terminated 7, Active not recruiting 2, Enrolling by invitation 2, Not yet recruiting 1
Early Phase 13Completed 2, Active not recruiting 1

Follow Gilead Sciences: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness
Lenacapavir, Cabotegravir, Bictegravir/Emtricitabine/Tenofovir Alafenamide - HIV Viremia
Phase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)382028-02-012026-11-16
ASTAR: Sacituzumab Govitecan For Breast Cancer
Sacituzumab Govitecan (SG), Cyclophosphamide, Docetaxel - Breast Cancer, HR Positive/HER-2 Negative Breast Cancer
Phase 2Not yet recruitingMassachusetts General Hospital322027-04-212026-11-19
Elimination of Hepatitis C Virus Among Users of Substances
Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] - Hepatitis C in Substance Users
Not yet recruitingInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran10002027-03-152026-11-06
Combating Related Epidemics in HCV
Cepheid GeneXpert HCV Test, INSTI HIV - 1/2 Antibody, bioLytical Laboratories iStatis Hepatitis B Surface Antigen Test - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
Phase 4Not yet recruitingDuke University12802027-01-202026-11-18
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
TUB-040 - NSCLC, Non Small Cell Lung Cancer
Phase 2Not yet recruitingGilead Sciences802026-11-012026-09-16
Tenofovir Exposures in Advanced Kidney Disease Study
Plasma sampling for tenofovir and emtricitabine, Descovy - Tenofovir, Tenofovir Alafenamide Fumarate
Not yet recruitingKing's College Hospital NHS Trust502026-11-012026-09-10
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill - Talaromycosis
Phase 3Not yet recruitingDuke University4282026-11-012026-09-21
Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes
GS-1179, GS-1179 PTM, Valacyclovir - HSV-2 Infection
Phase 2Not yet recruitingGilead Sciences3002026-11-012026-11-03
Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV
BIC/LEN FDC, Lenacapavir, SBR - HIV-1 Infection
Phase 4Not yet recruitingGilead Sciences4002026-11-012026-11-02
HIV/HBV/HCV Triple Screening in Primary Care
electronic medical record alert linked to orders - HIV, HBV (Hepatitis B Virus)
Not applicableRecruitingUniversity of Texas Southwestern Medical Center502026-11-012026-10-29
Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1
Lenacapavir Tablet, Lenacapavir Injection, Teropavimab - HIV-1-infection
Phase 2 / Phase 3Not yet recruitingGilead Sciences252026-11-012026-11-19
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
scalp cooling, photographs via the Belle.AI app, Antibody-Drug Conjugates - Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate
Phase 2RecruitingJules Bordet Institute1022026-10-232026-11-16
Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels
B/F/TAF, GS-3242, Lenacapavir - HIV-1 Infection
Phase 2RecruitingGilead Sciences1252026-10-012026-10-23
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
TUB-040 - Dose escalation, TUB-040 - RP2D - Uterine Endometrial Cancer
Phase 1 / Phase 2Not yet recruitingGilead Sciences1002026-10-012026-08-05
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
12 mg of nebulised 99mTc-liposomal amphotericin B, 24 mg of nebulised 99mTc-liposomal amphotericin B, SPECT/CT scan - Chronic Pulmonary Aspergillosis
Phase 1Not yet recruitingRadboud University Medical Center182026-10-012026-08-18
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
Seladelpar, PTM Seladelpar, Cilofexor Dose B - Primary Biliary Cholangitis
Phase 2RecruitingGilead Sciences1322026-10-012026-10-27
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2RecruitingVanderbilt-Ingram Cancer Center592026-09-252026-10-02
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection
Phase 3Not yet recruitingHIV Prevention Trials Network4002026-09-012026-06-22
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy - Breast Cancer, Triple-negative Breast Cancer
Phase 3Not yet recruitingWomen's Cancer Study Group GmbH7652026-08-302026-08-05
Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care
Research Assistant Support - Shared Decision-Making, Quality of Life
Not applicableRecruitingStanford University1382026-08-262026-08-27

Showing 20 of 1211. Sign in to see all of them.

Conditions studied

Hepatitis C (153)  ·  HIV Infections (141)  ·  Acquired Immunodeficiency Syndrome (91)  ·  Hepatitis C, Chronic (55)  ·  Hepatitis B (50)  ·  Hepatitis B, Chronic (46)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (44)  ·  Breast Neoplasms (38)  ·  Hepatitis (30)  ·  Cystic Fibrosis (26)  ·  Lymphoma, Non-Hodgkin (26)  ·  COVID-19 (24)  ·  Triple Negative Breast Neoplasms (22)  ·  Fibrosis (21)  ·  Hypertension, Pulmonary (20)

Interventions

Tenofovir (103)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (79)  ·  sacituzumab govitecan (71)  ·  Emtricitabine (59)  ·  Sofosbuvir (57)  ·  bictegravir, emtricitabine, tenofovir alafenamide, drug combination (49)  ·  Ranolazine (48)  ·  ledipasvir, sofosbuvir drug combination (46)  ·  sofosbuvir-velpatasvir drug combination (45)  ·  idelalisib (42)  ·  Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (40)  ·  Ribavirin (34)  ·  tenofovir alafenamide (29)  ·  emtricitabine tenofovir alafenamide (27)  ·  lenacapavir (27)

Countries

United States (811)  ·  France (222)  ·  United Kingdom (221)  ·  Canada (214)  ·  Germany (200)  ·  Spain (194)  ·  Australia (167)  ·  Italy (164)  ·  Belgium (118)  ·  Puerto Rico (111)  ·  Poland (96)  ·  New Zealand (94)  ·  South Korea (91)  ·  Netherlands (84)  ·  Austria (73)

Top investigators

William Wegener, MD, PhD (10)  ·  John Flaherty, PharmD (8)  ·  Robert H. Hyland, DPhil (6)  ·  Bittoo Kanwar, MD (5)  ·  John McNally, PhD (5)  ·  Patrick Yue, MD (5)  ·  Kathryn Kersey, MSc (4)  ·  Mark Bresnik, MD (4)  ·  Marshall Fordyce, MD (3)  ·  Peter Hodsman, MD (3)  ·  Robert H Hyland, DPhil (3)  ·  Shampa De-Oertel, PhD (3)

Results publications

PMID 35728046, PMID 36205910, PMID 37747626, PMID 25040192, PMID 25583164, PMID 27847279, PMID 33307033, PMID 36695483, PMID 36750244, PMID 37771546, PMID 19052126, PMID 25987775, PMID 27553375, PMID 29956087, PMID 30932951, PMID 34980223, PMID 36740893, PMID 36912172, PMID 38057656, PMID 38985247, PMID 40657894, PMID 19451441, PMID 20955704, PMID 21816833, PMID 23234725, PMID 23364953, PMID 23607593, PMID 23607594, PMID 23939953, PMID 24209977, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24908550, PMID 25154045, PMID 25179493, PMID 25277773, PMID 25532501, PMID 25788199, PMID 25890673, PMID 26472751, PMID 26542378, PMID 26575258, PMID 26743093, PMID 26829661, PMID 26892863, PMID 27248633, PMID 27658343, PMID 27742226, PMID 28076335

NIH funding

2015 (40), 2016 (39), 2014 (32), 2023 (18), 2019 (15), 2017 (14), 2018 (8), 2025 (7), 2008 (3), 2009 (3), R01MH110057 (3), 2004 (2), 2005 (2), U01AI068636 (2), U10CA031946 (2)